Propolis for Patients With Chronic Kidney Disease.

Brief summary (registry, in English)

To evaluate the effects of propolis extract on inflammation in participants with chronic kidney disease. Specific objectives To assess before and after the intervention period: * The expression of transcription factors (nuclear factor-kB), antioxidant enzymes (heme-oxygenase-1), inflammasome receptor, peroxisome proliferator-activated receptor-γ, as well as the levels of inflammatory cytokines (IL-6, Tumor nuclear factor-α, C-reactive protein, interleukin 1) and E-selectin adhesion molecules; * The levels of protein expression of inflammatory markers and antioxidant enzymes; * The profile of the intestinal microbiota of stool samples from the research participants; * Plasma levels of substances reactive to thiobarbituric acid and oxidized low density lipoprotein as a marker of oxidative stress; * Routine and anthropometric laboratory variables, indicative of the metabolic profile of the research participants; * Assess blood pressure, 6-minute walk test, recovery heart rate and chair lift test to assess the functional capacity of the research participants; * Assess atherogenic risk; * Food intake and nutritional status; Compare data between the intervention and control groups.

What you commit to

• Study type: Interventional
• Participants enrolled: 24
• From 12 Jan 2021 to the primary completion date, 29 Dec 2023
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.